novel LSD1 inhibitor

The "novel LSD1 inhibitor" refers to a class of compounds identified through a phenotypic cell-based screen (the YB5 system) designed to find epigenetic modulators that reactivate silenced genes. These compounds, derived from natural products and further optimized through medicinal chemistry, target Lysine-specific histone demethylase 1A (LSD1/KDM1A). LSD1 is an epigenetic enzyme that plays a critical role in maintaining the undifferentiated state of cancer cells and silencing tumor suppressor genes. Preclinical data presented at AACR 2016 demonstrated that these inhibitors can reactivate hypermethylated genes, induce G2/M cell cycle arrest, and significantly inhibit the proliferation of colon cancer and acute myeloid leukemia (AML) cells. The development was a collaborative effort involving the Fels Institute for Cancer Research, Temple University's Moulder Center for Drug Discovery Research, and Johns Hopkins University.

Other names

LSD1 inhibitorLSD-1 inhibitorLSD 1 inhibitorKDM1A inhibitorKDM-1A inhibitorKDM 1A inhibitor